GlobeImmune (GBIM) 10-Q/A 5 Sep 14 2014 Q2 Quarterly report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 01, 2014
Document And Entity Information [Line Items]	'	'
Document Type	'10-Q/A	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'GBIM	'
Entity Registrant Name	'GLOBEIMMUNE INC	'
Entity Central Index Key	'0001245104	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	5,748,979

Condensed_Balance_Sheets_unaud

Condensed Balance Sheets (unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$6,461,745	$5,924,241
Debt issuance costs	1,124,821	'
Other current assets	2,037,976	900,896
Total current assets	9,624,542	6,825,137
Property and equipment, net	488,634	492,802
Other assets	100,000	100,000
Total assets	10,213,176	7,417,939
Current liabilities:	'	'
Accounts payable	1,306,919	1,736,621
Accrued liabilities	1,054,893	920,962
Convertible notes	4,226,649	'
Fair value of warrants	6,704,120	13
Fair value of put and call options	3,347,037	'
Deferred revenue	3,378,706	3,756,899
Total current liabilities	20,018,324	6,414,495
Other long-term liabilities	231,278	223,029
Deferred revenue	9,047,644	10,656,976
Fair value of warrants, net of current portion	413,934	1,564,928
Convertible promissory note	247,948	197,955
Total liabilities	29,959,128	19,057,383
Commitments and contingencies	'	'
Stockholders' deficit:	'	'
Common stock, $0.001 par value. Authorized 112,500,000 shares; issued and outstanding 92,812 and 98,226 shares, respectively	98	93
Additional paid-in capital	'	'
Accumulated deficit	-214,303,548	-199,321,927
Total stockholders' deficit	-214,303,450	-199,321,834
Total liabilities, redeemable, convertible preferred stock and stockholders' deficit	10,213,176	7,417,939
Series C	'	'
Current liabilities:	'	'
Redeemable, convertible preferred stock	70,011,136	67,548,103
Series D	'	'
Current liabilities:	'	'
Redeemable, convertible preferred stock	13,598,503	12,964,405
Series E	'	'
Current liabilities:	'	'
Redeemable, convertible preferred stock	24,317,680	23,482,780
Series A	'	'
Current liabilities:	'	'
Redeemable, convertible preferred stock	16,223,155	15,670,621
Series B	'	'
Current liabilities:	'	'
Redeemable, convertible preferred stock	$70,407,024	$68,016,481

Condensed_Balance_Sheets_unaud1

Condensed Balance Sheets (unaudited) (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	112,500,000	112,500,000
Common stock, shares issued	98,226	92,812
Common stock, shares outstanding	98,226	92,812
Series C	'	'
Convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	37,600,000	37,600,000
Convertible preferred stock, issued	31,147,071	31,147,071
Convertible preferred stock, outstanding	31,147,071	31,147,071
Convertible preferred stock, liquidation preference	$70,325,906	$67,948,149
Series D	'	'
Convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	8,900,000	8,900,000
Convertible preferred stock, issued	8,650,519	8,650,519
Convertible preferred stock, outstanding	8,650,519	8,650,519
Convertible preferred stock, liquidation preference	14,170,303	13,691,114
Series E	'	'
Convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	11,750,000	11,750,000
Convertible preferred stock, issued	11,665,019	11,665,019
Convertible preferred stock, outstanding	11,665,019	11,665,019
Convertible preferred stock, liquidation preference	24,358,901	23,535,170
Series A	'	'
Convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	6,430,000	6,430,000
Convertible preferred stock, issued	6,407,998	6,407,998
Convertible preferred stock, outstanding	6,407,998	6,407,998
Convertible preferred stock, liquidation preference	16,236,311	15,687,341
Series B	'	'
Convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	29,300,000	29,300,000
Convertible preferred stock, issued	28,699,551	28,699,551
Convertible preferred stock, outstanding	28,699,551	28,699,551
Convertible preferred stock, liquidation preference	$70,438,623	$68,056,641

Condensed_Statements_of_Operat

Condensed Statements of Operations and Comprehensive Income and Loss (unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenue	'	'	'	'
Collaboration license and services	$1,153,018	$2,573,497	$2,436,539	$3,765,764
Manufacturing services	578,000	1,648,700	712,825	2,588,700
Total revenue	1,731,018	4,222,197	3,149,364	6,354,464
Research and development expenses:	'	'	'	'
Costs of collaboration license and services	925,141	536,276	1,757,995	2,649,192
Costs of manufacturing services	578,000	1,648,700	712,825	2,588,700
Research and development for proprietary programs	637,066	510,253	1,208,166	670,744
Total research and development	2,140,207	2,695,229	3,678,986	5,908,636
General and administrative	855,693	713,602	1,870,325	1,450,747
Depreciation and amortization	71,415	216,114	141,281	436,044
Total operating expenses	3,067,315	3,624,945	5,690,592	7,795,427
Income (loss) from operations	-1,336,297	597,252	-2,541,228	-1,440,963
Change in value of warrants and put and call options, income (expense)	-2,150,491	483,393	-1,903,446	969,974
Interest expense	-2,227,167	'	-3,713,853	'
Other income	'	63	'	125
Income (loss) before taxes	-5,713,955	1,080,708	-8,158,527	-470,864
Income taxes	'	'	'	'
Net income (loss)	-5,713,955	1,080,708	-8,158,527	-470,864
Preferred stock dividends and accretion of offering costs to redemption value	-3,437,556	-3,221,285	-6,875,108	-6,442,570
Net loss applicable to common stockholders	($9,151,511)	($2,140,577)	($15,033,635)	($6,913,434)
Weighted average shares outstanding-basic and diluted	98,067	92,430	95,622	92,430
Net loss per share attributable to common stockholders- basic and diluted	($93.32)	($23.16)	($157.22)	($74.80)
Pro forma net income per share of common stock attributable to GlobeImmune, Inc. stockholders - diluted (note 3(e))	($1.25)	'	($2.19)	'
Pro forma weighted-average common shares outstanding-diluted (note 3(e))	2,855,892	'	2,853,447	'

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($8,158,527)	($470,864)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	141,281	436,044
Share-based compensation	46,506	109,752
Stock-based payments for services	-20,000	17,142
Noncash interest expense from amortization of debt discount and amortization of debt issuance costs	3,388,319	'
Noncash interest expense on convertible notes	313,299	'
Noncash expense (income) from change in valuation of warrants and put and call options	1,903,446	-969,974
Gain on sale of property and equipment	-91,285	'
Changes in operating assets and liabilities:	'	'
Decrease in other current assets	-1,137,080	-238,153
Increase (decrease) in accounts payable	-429,702	1,577,662
Increase (decrease) in accrued liabilities	133,931	-920,274
Decrease in deferred revenue	-1,987,525	-1,200,014
Increase in other long-term liabilities	6,643	'
Net cash used in operating activities	-5,890,694	-1,658,679
Cash flows from investing activities:	'	'
Purchase of property and equipment	-173,182	-12,233
Sale of property and equipment	127,354	'
Net cash used in investing activities	-45,828	-12,233
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock	25,513	'
Proceeds from issuance of convertible notes payable	7,500,000	'
Convertible promissory notes issuance costs	-1,051,487	'
Net cash provided by financing activities	6,474,026	'
Net increase (decrease) in cash and cash equivalents	537,504	-1,670,912
Cash and cash equivalents, beginning of period	5,924,241	2,002,948
Cash and cash equivalents, end of period	6,461,745	332,036
Supplemental disclosures of noncash investing and financing activities:	'	'
Accretion of preferred stock (dividends)	6,611,629	6,179,092
Accretion of preferred stock (offering costs)	263,479	263,478
Fair value of warrants and put option issued in connection with convertible note payable	6,121,533	'
Fair value of warrants issued for debt issuance costs	$876,778	'

Organization_and_Nature_of_Bus

Organization and Nature of Business	6 Months Ended
	Jun. 30, 2014
Organization and Nature of Business	'
	(1)Organization and Nature of Business
	We were incorporated as Ceres Pharmaceuticals, Ltd. in Colorado on February 10, 1995. We changed our name to GlobeImmune, Inc. on May 26, 2001, and reincorporated in Delaware on June 5, 2002. We are a biopharmaceutical company focused on developing therapeutic products for cancer and infectious diseases based on our proprietary Tarmogen ® platform. We have two strategic collaborations with leading biotechnology companies. In October 2011, Gilead Sciences, Inc., or Gilead, exclusively licensed product candidates to treat chronic hepatitis B virus, or HBV, infection. Celgene Corporation, or Celgene, entered into a collaboration and option agreement for certain oncology product candidates in May 2009. Under this agreement, in July 2013 Celgene exercised its option for a worldwide, exclusive license to the GI-6300 program, which is a Tarmogens program targeting the brachyury protein. We have four product candidates in five ongoing clinical trials.
	Our operations are subject to certain risks and uncertainties. The risks include negative outcome of clinical trials, inability or delay in completing clinical trials or obtaining regulatory approvals, changing market conditions for products being developed by us, more stringent regulatory environment, the need to retain key personnel and protect intellectual property, product liability, and the availability of additional capital financing on terms acceptable to us. Because of the numerous risks and uncertainties associated with biopharmaceutical product development and commercialization, we are unable to accurately predict the timing or amount of future expenses or when, or if, it will be able to achieve or maintain profitability. Currently, we have no products approved for commercial sale, and to date we have not generated any product revenue. We have financed our operations primarily through the sale of equity securities, upfront payments pursuant to collaboration agreements, government grants and equipment financing. The size of our future net losses will depend, in part, on the rate of growth or contraction of expenses and the level and rate of growth, if any, of revenues. Our ability to achieve profitability is dependent on our ability, alone or with others, to complete the development of our product candidates successfully, obtain the required regulatory approvals, manufacture and market our proposed products successfully or have such products manufactured and marketed by others and gain market acceptance for such products. There can be no assurance as to whether or when we will achieve profitability.

Liquidity_Risks

Liquidity Risks	6 Months Ended
	Jun. 30, 2014
Liquidity Risks	'
	-2	Liquidity Risks
	We have incurred operating losses and have an accumulated deficit as a result of ongoing research and development spending. As of June 30, 2014, we had an accumulated deficit of $214,303,548. We had net losses of $5,713,955 and $8,158,527 for the three and six months ended June 30, 2014, respectively, and net cash used in operating activities of $5,890,694 for the six months ended June 30, 2014. We anticipate that operating losses and net cash used in operating activities will occur and substantially increase over the next several years as we expand discovery, research and development activities, including clinical development of our Tarmogen product candidates.
	We have historically financed our operations primarily through the sale of equity securities, payments pursuant to collaboration agreements, government grants and equipment financing. We will continue to be dependent upon such sources of funds until we are able to generate positive cash flows from our operations. We believe that our existing cash and cash equivalents as of June 30, 2014 as well as amounts raised subsequent to June 30, 2014 through the issuance of common stock in an initial public offering will be sufficient to fund operations through 2015.
	We will be required to fund future operations through the sale of our equity securities, issuance of convertible debt, potential milestone payments, if achieved, and possible future collaboration. There can be no assurance that sufficient funds will be available to us when needed from equity or convertible debt financings, that milestone payments will be earned or that future collaboration partnerships will be entered into. If we are unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce our current rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and development programs. Insufficient liquidity may also require us to relinquish greater rights to product candidates at an earlier stage of development or on less favorable terms to us or our stockholders than we would otherwise choose. These events could prevent us from successfully executing on our operating plan and could raise substantial doubt about our ability to continue as a going concern in future periods.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Summary of Significant Accounting Policies	'
	-3	Summary of Significant Accounting Policies
	(a)	Use of Estimates in the Preparation of Financial Statements
	The preparation of the financial statements in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, requires our management to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates in the accompanying financial statements relate to the estimated useful lives of property and equipment; the terms of performance under collaboration agreements; the estimated fair values of warrants for redeemable, convertible preferred stock; and the estimated fair values of share-based awards, including the estimated fair value of the underlying common stock.
	(b)	Unaudited Interim Financial Data
	The accompanying condensed balance sheet as of June 30, 2014, condensed statements of operations and comprehensive income and loss for the three months ended and the six months ended June 30, 2013 and 2014 and condensed statements of cash flows for the six months ended June 30, 2013 and 2014 are unaudited. The unaudited interim financial statements have been prepared on a basis consistent with the audited financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) considered necessary to state fairly our financial position as of June 30, 2014 and the results of operations for the three and six months ended June 30, 2013 and 2014 and cash flows for the six months ended June 30, 2014. The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2013 and 2014 are unaudited. The results for the three months and six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other interim period.  These unaudited financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2013 included in our Prospectus filed on July 2, 2014 with the United States Securities and Exchange Commission, or the SEC, pursuant to Rule 424(b)(4).
	(c)	Reverse Stock Split
	On April 25, 2014, we affected a 1-for-4.3 reverse stock split of our common stock after approval by our stockholders. In connection with the reverse stock split, we filed a Certificate of Amendment of our Restated Certificate of Incorporation with the Secretary of State of Delaware on April 25, 2014 affecting the reverse stock split. This reverse stock split has been reflected retroactively for all periods presented in the financial statements.
	(d)	Accrued Liabilities
	We make estimates of our accrued expenses by identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of actual cost. The majority of our service providers invoice us monthly in arrears for services performed. Examples of estimated accrued expenses include:
	·	fees owed to contract research organizations in connection with preclinical and toxicology studies and clinical trials;
	·	fees owed to investigative sites in connection with clinical trials;
	·	fees owed to contract manufacturers in connection with the production of clinical trial materials;
	·	fees owed for professional services;
	·	property taxes; and
	·	unpaid salaries, wages, and benefits.
	Accrued liabilities consisted of the following as of:
		December 31,			June 30,
		2013			2014
	Accrued compensation	$	278,108			288,672
	Accrued clinical trial holdbacks		126,455			107,196
	Income taxes		115,765		—
	Other		400,634			659,025
	Total Accrued Liabilities	$	920,962			1,054,893
	As of December 31, 2013 and June 30, 2014, accrued liabilities included $126,455 and $107,196 respectively, of holdbacks representing five percent of payments due to entities conducting clinical trials for patient-related fees. The holdbacks will be paid upon completion of the studies and when all data has been received and validated by us.
	(e)	Net Loss per Share
	Basic net loss per share is computed by dividing net loss applicable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In the periods with net losses, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.
		Three Months Ended June 30,						Six Months Ended June 30,
		2013			2014			2013			2014
	Historical net loss per share:
	Numerator:
	Net loss attributable to GlobeImmune, Inc. common stockholders		(2,140,577	)		(9,151,511	)		(6,913,434	)		(15,033,635	)
	Denominator:
	Weighted-average common shares used in computing		92,430			98,067			92,430			95,622
	net loss per share of common stock - basic and diluted
	Net loss per share of common stock attributable to		(23.16	)		(93.32	)		(74.80	)		(157.22	)
	GlobeImmune, Inc. stockholders - basic and
	diluted
	Pro forma net income per share:
	Numerator:
	Net loss attributable to GlobeImmune, Inc. common stockholders				$	(9,151,511	)				$	(15,033,635	)
	Deduct:  income on change in fair value of warrant					2,150,491						1,903,446
	liability
	Add back:  interest expense on convertible				(*		)				(*		)
	promissory notes
	Add back:  Preferred stock dividends and accretion					3,437,556						6,875,108
	of offering costs to redemption value
	Net income used in computing pro forma net income				$	(3,563,464	)				$	(6,255,081	)
	per share of common stock attributable to
	GlobeImmune, Inc. stockholders - diluted
	Denominator:
	Basic and diluted weighted-average common shares, as					98,067						95,622
	used above
	Add back: pro forma adjustment to reflect weighted-					2,757,825						2,757,825
	average of assumed conversion of convertible
	preferred stock   (1)
	Add back:  pro forma adjustment to reflect weighted-				(*		)				(*		)
	average convertible promissory note on an if-
	converted basis
	Add back:  incremental stock options on a treasury				(*		)				(*		)
	stock method
	Weighted-average shares used in computing pro forma					2,855,892						2,853,447
	diluted net income per common share
	Pro forma net income per share of common stock				$	(1.25	)				$	(2.19	)
attributable to GlobeImmune, Inc. stockholders -
diluted
(*)	Balance and shares were excluded for the three and six months ended June 30, 2014 calculation as they were anti-dilutive.
-1	The pro forma net income per share reflects the assumed conversion of all outstanding shares of redeemable, convertible preferred stock as of June 30, 2014 into 2,757,825 shares of common stock. This conversion occurred upon the closing of our initial public offering. The numerator in the pro forma diluted net income per share calculation has been adjusted to remove the preferred stock dividends and accretion of offering costs to redemption value as this charge was eliminated upon the conversion of all outstanding shares of redeemable, convertible preferred stock upon receipt of the consent of a majority of our preferred stockholders. In addition, the numerator in the pro forma diluted net income per share calculation has been adjusted for income resulting from remeasurement of the preferred stock warrant liability as these measurements were no longer required when the preferred stock warrants became warrants to purchase shares of our common stock upon the closing of our initial public offering.
(f)	Recently Issued Accounting Standards
On May 28, 2014, the Financial Accounting Standards Board, or FASB, issued the Accounting Standards Update, or ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606), that will supersede nearly all existing revenue recognition guidance under U.S. GAAP.  This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The guidance will replace most existing revenue recognition guidance when it becomes effective. The standard will be effective for us for annual and interim periods beginning after December 15, 2016, and early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect that this new guidance will have on our consolidated financial statements and related disclosures. We have not selected a transition method nor have we determined the effect of the standard on our ongoing financial reporting.
(g)	Fair Value Measurements
The carrying amounts of financial instruments, including cash and cash equivalents, accrued compensation, accrued clinical holdbacks and accounts payable, approximate fair value due to their short-term maturities. The carrying amount of the convertible note payable approximates its fair value as its terms are comparable to what would be included in similar debt instruments.
We account for our preferred stock warrants pursuant to ASC Topic 480, Distinguishing Liabilities from Equity, and classify warrants for redeemable preferred stock as liabilities. The warrants are reported as short-term or long-term liabilities, depending on their remaining term, at their estimated fair value at December 31, 2013 and June 30, 2014, and any changes in fair value are reflected in changes in value of warrants.
The fair value of all the outstanding warrants at December 31, 2013 and June 30, 2014 was $1,564,941 and $7,118,054, respectively.
In general, asset and liability fair values are determined using the following categories:
Level 1– inputs utilize quoted prices in active markets for identical assets or liabilities.
Level 2– inputs include quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
Level 3– inputs are unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing inputs are unobservable for the terms and are based on our own assumptions about the assumptions that a market participant would use.
Our financial instruments, including money market investments, warrants, and put options are measured at fair value on a recurring basis. The carrying amount of money market investments as of December 31, 2013 and June 30, 2014 approximates fair value based on quoted prices in active markets, or Level 1 inputs. The carrying amount of outstanding warrants and put options as of December 31, 2013 and June 30, 2014 approximates fair value based on unobservable inputs, or Level 3 inputs, using assumptions made by us, including pricing, volatility, and expected term. There were no transfers between levels for the year ended December 31, 2013 and the three and six months ended June 30, 2014.
Assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of December 31, 2013 and June 30, 2014:
Description	December 31,			Quoted			Significant			June 30,			Quoted		Significant
	2013			prices in			unobservable			2014			prices in		unobservable
				active			inputs						active		inputs
				markets for			(Level 3)						markets for		(Level 3)
				identical									identical
				assets									assets
				(Level 1)									(Level 1)
Assets measured at fair value:
Money market investments (included in		20,672			20,672			—			20,422			20,422		—
cash and cash equivalents)
Liabilities measured at fair value:
Warrants (included in fair value of		1,564,941			—			1,564,941			7,118,054			—		7,118,054
warrants)
Put and call options (included in fair		101,222			—			101,222			3,449,866			—		3,449,866
value of put and call options and
other long-term liabilities)
A reconciliation of the beginning and ending balances of our assets and liabilities measured at fair value using significant unobservable, or Level 3, inputs is as follows:
	Warrants			Put and call options
Balance of liability at December 31, 2013	$	(1,564,941	)		(101,222	)
Issuance of warrants in connection with		(5,331,175	)	—
convertible promissory notes
Issuance of put and call options in	—				(1,667,136	)
connection with convertible
promissory notes
Income (loss) included in net loss:
Loss due to change in fair value		(221,938	)		(1,681,508	)
Balance of liability at June 30, 2014	$	(7,118,054	)		(3,449,866	)
Gains (losses) included in net income and loss for the six months ended June 30, 2014 are reported in change in value of warrants.

Convertable_Notes

Convertable Notes	6 Months Ended
	Jun. 30, 2014
Convertible Notes	'
	-4	Convertible Notes
	2013 Notes
	In November 2013, we entered into an unsecured convertible promissory note, or the Note, with a service provider, or the Holder, in settlement of $391,730 of accounts payable. The Note bears an interest rate of 8.0%, has a term of three years and can be prepaid at any time. The Note and unpaid accrued interest converted upon the completion of our initial public offering into common stock at a price per share equal to 80% at which our common stock was first offered to the public. The Holder also received a warrant, equal to 30% of the principal balance of the Note, to purchase common stock for 10 years with an exercise price equal to the conversion price.
	We recorded the proceeds from the Note based on the fair value of the warrants ($106,087), put option embedded in the Note ($101,222) and the Note and, as such, recorded a debt discount of $207,309 for the allocated value of the warrants and put option. This debt discount is being amortized to interest expense over the term of the Note. Amortization of $17,213 and $34,236 was recorded in the three and six months ended June 30, 2014, respectively, and the unamortized balance of the debt discount was $198,041 and $163,804 as of December 31, 2013 and June 30, 2014, respectively. As of December 31, 2013 and June 30, 2014, the Note balance includes accrued interest of $4,266 and $20,022, respectively.
	The estimated fair value of the Note as of December 31, 2013 and June 30, 2014 approximated its carrying value.
	2014 Convertible Notes
	In January and February 2014, we entered into unsecured convertible notes, the 2014 Notes, with various holders for a total aggregate principal amount of $7,500,000. The 2014 Notes bear an interest rate of 10.0% and have a maturity date of January 31, 2015. We cannot make any payments of principal and interest without the consent of a majority of the holders. The 2014 Notes are not convertible at the option of the holders. The 2014 Notes and unpaid accrued interest converted upon the completion of our initial public offering into common stock at a price equal to 70% of the price at which our common stock was first offered to the public.
	The holders of the 2014 Notes received warrants, equal to 100% of the principal amount of the 2014 Notes to purchase equity securities of us for a five-year period. As a result of our initial public offering, the warrants are exercisable into common stock with an exercise price equal to the price at which our common stock was first offered to the public.
	We recorded the proceeds from the 2014 Notes based on the fair value of the warrants ($4,454,397), the net of the put and call option embedded in the 2014 Notes ($1,667,136) and the 2014 Notes. As such, we recorded a debt discount of $6,121,533 from the allocated value of the warrants and the put and call options. This debt discount is being amortized to interest expense over the term of the 2014 Notes. Amortization of $1,530,383 and $2,559,639 was recorded in the three and six month period ended June 30, 2014 and the unamortized balance of the debt discount was $3,570,894 as of June 30, 2014. As of June 30, 2014, the 2014 Notes balance includes accrued interest of $297,543.
	We incurred $1,928,265 of debt issuance costs related to the 2014 Notes. Included in the debt issuance costs were warrants issued to the placement agent that had an estimated value of $876,778 at issuance. These costs are included in debt issuance costs and are being amortized to interest expense over the term of the 2014 Notes. Amortization of $482,066 and $803,444 was recorded in the three and six month periods ended June 30, 2014, respectively, and the unamortized balance of the debt issuance costs was $1,124,821 as of June 30, 2014.
	The estimated fair value of the 2014 Notes as of June 30, 2014 approximated its carrying value.

Deferred_Revenue

Deferred Revenue	6 Months Ended
	Jun. 30, 2014
Deferred Revenue	'
	-5	Deferred Revenue
	Deferred revenue consisted of the following as of:
		31-Dec-13			30-Jun-14
	Celgene	$	14,169,164			12,390,655
	Gilead		244,711			35,695
	Total deferred revenue		14,413,875			12,426,350
	Less:  current portion		(3,756,899	)		(3,378,706	)
	Deferred revenue, long-term	$	10,656,976			9,047,644
	(a)	Celgene Agreements
	In May 2009, we entered into a Collaboration and Option Agreement with Celgene for the early development of four oncology products and all future oncology drug candidates (which options to future oncology drug candidates is subject to expiration if Celgene did not license one of the initial four named products). Celgene is also a holder of our common stock. Under the collaboration agreement, Celgene has the option to obtain an exclusive worldwide license to develop and commercialize the product candidates subject to diligence requirements, an up-front development funding fee, milestone payments and royalties. This agreement was amended in June 2011 to replace one of the four named product candidates with another oncology Tarmogen product candidate. The terms of the amendment did not materially modify the agreement as the financial terms and the length of the agreement remained substantially the same. Celgene’s options with respect to the GI-6200 and GI-3000 oncology drug candidate programs will terminate if Celgene does not exercise its options for such programs after we deliver certain reports on predefined clinical trials with respect to such drug programs. In March 2013, Celgene declined to exercise its option to the GI-4000 program and returned all rights and development responsibility to us. In July 2013, Celgene exercised its option to license the GI-6300 program. As a result of the election to license the GI-6300 program, Celgene has an option to license all future oncology drug candidates developed by us on a product by product basis.
	In July 2013, Celgene exercised its option to license the GI-6300 program, including GI- 6301, in exchange for an upfront payment of $9,000,000. As part of that exercise, the Collaboration and Option Agreement was amended as it related to the GI-6300 program. The agreement, as amended, includes (1) a license granted to Celgene as of the date of the exercise of the option to develop and commercialize the GI-6300 product candidates using all of our related patents, intellectual property and know-how related to these product candidates that existed at the inception of the Collaboration and Option Agreement or any time during the term, (2) us supplying drug product for the Phase 2 clinical trial and (3) our option to perform Phase 2 clinical trials, subject to Celgene’s right to assume performance of those trials. As part of this exercise, certain milestones were modified and adjustments to the royalty rates on net sales were reduced. The modification to the milestones did not materially impact the deliverables that existed at the time of the modification.
	The Collaboration and Option agreement, as amended including the amendment relating to the GI-6300 program contain the following provisions:
	·	We received a $30,000,000 upfront payment to perform research and development and for the option to license products based on the GI-4000, GI-6200, GI-6300 and GI-3000 programs. This payment was made by Celgene in May 2009.
	·	We received $1,000,000 in October 2011 and $300,000 in April 2012 from Celgene for additional immunology work for the GI-4000 program.
	·	We may receive a total of $85,000,000 in development and regulatory milestones for the GI-6200 and GI-3000 programs; activities for which we are not responsible for completing.
	·	If Celgene exercises its option to the GI-6200 or GI-3000 program and these products are commercialized, we may also receive up to $60,000,000 in net sales milestones and tiered royalty rates on net sales in the teens on worldwide net sales; activities for which we are not responsible for completing.
	·	We are eligible to receive a total of $85,000,000 in development and regulatory milestone payments for GI-6301; activities for which we are not responsible for completing.
	·	If GI-6301 is commercialized by Celgene, we may receive up to $60,000,000 in sales milestone payments for which we are not responsible for completing and tiered royalty rates on net sales ranging from single digits to low double digits.
	·	For programs other than GI-6200, GI-3000 and GI-6300, we may be eligible to receive up to $101,000,000 in development and regulatory milestone payments for Celgene’s clinical trials, NDA filing and regulatory approvals, up to $60,000,000 in net sales milestone payments for such programs, and tiered royalty rates on net sales in the teens on worldwide net sales; activities for which we are not responsible for completing.
	Upon execution of the May 2009 agreement, we estimated that our obligations to perform research and development under the agreement would continue through September 30, 2016 and accordingly recognized as revenue the upfront fees received of $31,300,000 from the date of receipt through September 30, 2016. We review the term of performance on a quarterly basis and adjust the revenue recognition period if there are any changes. As of December 31, 2013 and June 30, 2014, the unamortized balance was amortized on a straight line basis through March 31, 2018.
	We determined that there were two units of accounting under the July 2013 GI-6300 License Agreement with Celgene: the license to further develop and commercialize GI-6300 and undelivered items related to supplying drug product for the Phase 1 clinical trial and the option to perform the Phase 2 clinical trial (subject to Celgene’s right to assume performance of those trials). We determined that the license had standalone value based on the fact that the drug candidate has been developed and is currently in a clinical trial, Celgene possesses the knowledge, technology, skills, experience and background necessary for all further development of the drug through commercialization, we are not required to perform any additional development work related to GI-6300 and Celgene has the right to sublicense the product. We allocated the $9,000,000 of proceeds to the two units of accounting using the relative selling price method. We determined the estimated selling price for the license based upon a third party valuation and vendor specific objective evidence for the undelivered items. The allocation resulted in $8,766,881 being allocated to the license and the remaining amount of $233,119 allocated to the undelivered items. We recognized $8,766,881 in revenue related to the license in the fourth quarter of 2013 upon the delivery of all intellectual property, reports and documentation for the license to Celgene. Revenue related to the undelivered items will be recognized as the services are performed. The current estimated service period for the undelivered items under the GI-6300 License Agreement is through December 2014.
	We recognized $819,767, $819,767, $1,667,803 and $1,778,510 in revenue related to research and development services and other services during the three and six months ended June 30, 2013 and 2014, respectively. Costs incurred under these agreements, included in costs of collaboration licenses and services in our statement of operations and comprehensive income and loss, for the three and six months ended June 30, 2013 and 2014 were $390,202, $742,902, $1,496,486 and $1,356,857, respectively.
	To date, we have not recognized any revenue in connection with milestone payments, other than the license election noted above, or royalties under this agreement.
	(b)	Gilead Agreement
	In October 2011, we entered into a License and Collaboration Agreement with Gilead, granting Gilead an exclusive license to all hepatitis B Tarmogen product candidates to be developed and commercialized under the collaboration, which includes a license granted at contract outset to develop and commercialize the HBV Tarmogen product candidate GS-4774 using all of our related patents, intellectual property and know-how related to these product candidates. Under the terms of the agreement, in November 2011 Gilead made a $10,000,000 initial nonrefundable payment to us. We conducted preclinical development, filed the Investigational New Drug application, or IND, and performed the initial Phase 1a trial in healthy volunteers for the selected HBV Tarmogen. Gilead reimbursed us on a periodic basis for the costs and expenses of the Phase 1a clinical trial. Gilead will perform any future clinical development, regulatory and commercialization activities. Gilead activities are subject to commercially reasonable diligence, milestone payments and royalties. Upon satisfaction of certain substantive milestone events for which we were partially responsible for completing, we received $2,000,000 upon filing an IND for HBV in 2012 and $3,000,000 at the point of commencement of the Phase 1b/2a clinical trial in 2013. We are also eligible to receive additional proceeds of up to $130,000,000 in development and regulatory milestones based upon achievement of such milestones by Gilead. If products are commercialized, we are eligible to receive tiered royalty rates in the upper single digit to mid-teens and up to $40,000,000 of sales milestone payments based on net sales of the licensed product candidates. We are not responsible for the sales efforts.
	We determined there was one unit of accounting under the agreement with Gilead. The non-contingent deliverables under the agreement include: (i) the license to all intellectual property and know-how related to hepatitis B Tarmogen products, (ii) the services to be performed in preclinical development (including the filing of an IND) and in conducting the Phase 1a clinical trial, (iii) participation on the Joint Research and Development Committee, or JRC, and (iv) the requirement to provide consultation to Gilead after Gilead assumes control of development activities. We have estimated the performance period for these deliverables to be from October 2011 through 2020.
	When the agreement was signed, we determined that our obligation to supply drug product to Gilead after Gilead assumed control of the development was a contingent deliverable, as the obligation to supply product was contingent on the successful development of the hepatitis B Tarmogen product candidate and the related approval of the IND among other items. Subsequently, Gilead has assumed control of manufacturing. However, a services agreement between the parties also continues to exist. As a result, the services agreement deliverables and the potential incremental fees to be received by us will be accounted for only if and when delivery takes place. We have determined that the consideration to be received is an appropriate incremental fee and, therefore there is not a significant incremental discount associated with the selling price of the services agreement.
	We determined that the license did not have standalone value at the inception of the agreement. This determination is based on the fact that the license is not sold on a standalone basis, nor could it be resold by Gilead on a standalone basis because we have proprietary knowledge, technology, skills, experience and background that no other third party, including Gilead, currently possesses and could not readily obtain at contract inception. Such knowledge, technology, skills, experience and background would be necessary for further development of the hepatitis B Tarmogen product candidate as required under the agreement.
	We are recognizing the initial consideration of $10,000,000 and the amounts we will receive as reimbursement from Gilead of costs to perform the initial Phase 1a trial on a proportional performance basis over the estimated period of performance to complete the preclinical development and Phase 1a trial services, JRC and consultation services, which is estimated to be from October 2011 through 2020. We will measure our progress under the proportional performance method based on hours incurred in proportion to total estimated hours. However, the cumulative revenue recognized under this agreement will be limited to the cumulative cash received to date from Gilead. We incurred substantially all of our hours during the preclinical development and Phase 1a trial period, which ended in February 2014.
	The contractual term of the license is on a product and country basis that begins on the effective date of the contract, October 2011, and runs through the expiration of Gilead’s obligation to pay royalties for such product in such country, or until the agreement is terminated. The JRC term is from the effective date of the agreement and terminates at the end of the Research Term, which is the period of time commencing on the date the agreement was signed and ending upon completion of the final clinical study report for the Gilead Phase 1b/2a trial. The consulting term begins upon the conclusion of the Research Term, and we estimate the term would end upon commercialization, currently estimated in 2020.
	We recognized $1,741,829, $1,373, $2,086,061 and $218,646 in license and services revenue under the Gilead arrangement during the three and six months ended June 30, 2013 and 2014, respectively. We also recognized a milestone payment of $3,000,000 in the second half of 2013. In addition, we recognized revenue of $1,648,700, $578,000, $2,588,700 and $712,825  during the three and six months ended June 30, 2013 and 2014, respectively, related to manufacturing supply for Phase 2 trials for which Gilead is responsible for performing. Collaboration license and service costs incurred under these agreements, included in costs of collaboration licenses and services in our statement of operations and comprehensive income and loss, for the three and six months ended June 30, 2013 and 2014 were $146,074, $182,239, $1,179,706 and $401,138, respectively. Manufacturing services costs incurred under agreements with Gilead are included in costs of manufacturing services in our statement of operations and comprehensive income and loss, for the three and six months ended June 30, 2013 and 2014 were $1,648,700, $578,000, $2,588,700 and $712,825, respectively.

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Taxes	'
	-6	Income Taxes
	We maintain a valuation allowance for substantially all of our deferred tax assets, including our net operating losses, and therefore do not expect to incur a current U.S. federal tax expense or benefit against our pretax income (loss) during the year ending December 31, 2014.
	Our ability to realize the benefit of our deferred tax assets in future periods will depend on the generation of future taxable income and tax planning strategies. Due to our history of losses we have recorded a full valuation allowance against substantially all of our deferred tax assets. We do not expect to reduce the valuation allowance against our deferred tax assets to below 100% of our gross amount until we have a sufficient historical trend of taxable income and can predict future income with a higher degree of certainty.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events	'
	-7	Subsequent Events
	We completed an initial public offering on July 8, 2014.  In the offering, we sold 1,725,000 shares of our common stock, including those shares sold pursuant to the underwriter’s exercise of its over-allotment option, at $10.00 per share and raised $17,250,000 before fees and expenses.  Upon completion of the offering, all of our then outstanding preferred stock converted into 2,757,825 shares of our common stock in accordance with the terms of the preferred stock, all of our outstanding preferred stock warrants were reclassified into additional paid-in capital as all of the preferred stock warrants converted into common stock warrants, the Note and the 2014 Notes, described in note 4, converted into 51,556 and 1,116,372 shares of common stock, respectively, and the warrant issued to the holder of the Note upon such conversion and the warrants issued to the holders of the 2014 Notes become exercisable for 12,373 and 750,000 shares of common stock, respectively.  See our Prospectus filed on July 2, 2014 with the SEC pursuant to Rule 424(b)(4) for more information.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Use of Estimates in the Preparation of Financial Statements	'
	(a)	Use of Estimates in the Preparation of Financial Statements
	The preparation of the financial statements in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, requires our management to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates in the accompanying financial statements relate to the estimated useful lives of property and equipment; the terms of performance under collaboration agreements; the estimated fair values of warrants for redeemable, convertible preferred stock; and the estimated fair values of share-based awards, including the estimated fair value of the underlying common stock.
Unaudited Interim Financial Data	'
	(b)	Unaudited Interim Financial Data
	The accompanying condensed balance sheet as of June 30, 2014, condensed statements of operations and comprehensive income and loss for the three months ended and the six months ended June 30, 2013 and 2014 and condensed statements of cash flows for the six months ended June 30, 2013 and 2014 are unaudited. The unaudited interim financial statements have been prepared on a basis consistent with the audited financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) considered necessary to state fairly our financial position as of June 30, 2014 and the results of operations for the three and six months ended June 30, 2013 and 2014 and cash flows for the six months ended June 30, 2014. The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2013 and 2014 are unaudited. The results for the three months and six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other interim period.  These unaudited financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2013 included in our Prospectus filed on July 2, 2014 with the United States Securities and Exchange Commission, or the SEC, pursuant to Rule 424(b)(4).
Reverse Stock Split	'
	(c)	Reverse Stock Split
	On April 25, 2014, we affected a 1-for-4.3 reverse stock split of our common stock after approval by our stockholders. In connection with the reverse stock split, we filed a Certificate of Amendment of our Restated Certificate of Incorporation with the Secretary of State of Delaware on April 25, 2014 affecting the reverse stock split. This reverse stock split has been reflected retroactively for all periods presented in the financial statements.
Accrued bLiabilities	'
	(d)	Accrued Liabilities
	We make estimates of our accrued expenses by identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of actual cost. The majority of our service providers invoice us monthly in arrears for services performed. Examples of estimated accrued expenses include:
	·	fees owed to contract research organizations in connection with preclinical and toxicology studies and clinical trials;
	·	fees owed to investigative sites in connection with clinical trials;
	·	fees owed to contract manufacturers in connection with the production of clinical trial materials;
	·	fees owed for professional services;
	·	property taxes; and
	·	unpaid salaries, wages, and benefits.
	Accrued liabilities consisted of the following as of:
		December 31,			June 30,
		2013			2014
	Accrued compensation	$	278,108			288,672
	Accrued clinical trial holdbacks		126,455			107,196
	Income taxes		115,765		—
	Other		400,634			659,025
	Total Accrued Liabilities	$	920,962			1,054,893
	As of December 31, 2013 and June 30, 2014, accrued liabilities included $126,455 and $107,196 respectively, of holdbacks representing five percent of payments due to entities conducting clinical trials for patient-related fees. The holdbacks will be paid upon completion of the studies and when all data has been received and validated by us.
Net Loss Per Share	'
	(e)	Net Loss per Share
	Basic net loss per share is computed by dividing net loss applicable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In the periods with net losses, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.
		Three Months Ended June 30,						Six Months Ended June 30,
		2013			2014			2013			2014
	Historical net loss per share:
	Numerator:
	Net loss attributable to GlobeImmune, Inc. common stockholders		(2,140,577	)		(9,151,511	)		(6,913,434	)		(15,033,635	)
	Denominator:
	Weighted-average common shares used in computing		92,430			98,067			92,430			95,622
	net loss per share of common stock - basic and diluted
	Net loss per share of common stock attributable to		(23.16	)		(93.32	)		(74.80	)		(157.22	)
	GlobeImmune, Inc. stockholders - basic and
	diluted
	Pro forma net income per share:
	Numerator:
	Net loss attributable to GlobeImmune, Inc. common stockholders				$	(9,151,511	)				$	(15,033,635	)
	Deduct:  income on change in fair value of warrant					2,150,491						1,903,446
	liability
	Add back:  interest expense on convertible				(*		)				(*		)
	promissory notes
	Add back:  Preferred stock dividends and accretion					3,437,556						6,875,108
	of offering costs to redemption value
	Net income used in computing pro forma net income				$	(3,563,464	)				$	(6,255,081	)
	per share of common stock attributable to
	GlobeImmune, Inc. stockholders - diluted
	Denominator:
	Basic and diluted weighted-average common shares, as					98,067						95,622
	used above
	Add back: pro forma adjustment to reflect weighted-					2,757,825						2,757,825
	average of assumed conversion of convertible
	preferred stock   (1)
	Add back:  pro forma adjustment to reflect weighted-				(*		)				(*		)
	average convertible promissory note on an if-
	converted basis
	Add back:  incremental stock options on a treasury				(*		)				(*		)
	stock method
	Weighted-average shares used in computing pro forma					2,855,892						2,853,447
	diluted net income per common share
	Pro forma net income per share of common stock				$	(1.25	)				$	(2.19	)
	attributable to GlobeImmune, Inc. stockholders -
	diluted
	(*)	Balance and shares were excluded for the three and six months ended June 30, 2014 calculation as they were anti-dilutive.
	-1	The pro forma net income per share reflects the assumed conversion of all outstanding shares of redeemable, convertible preferred stock as of June 30, 2014 into 2,757,825 shares of common stock. This conversion occurred upon the closing of our initial public offering. The numerator in the pro forma diluted net income per share calculation has been adjusted to remove the preferred stock dividends and accretion of offering costs to redemption value as this charge was eliminated upon the conversion of all outstanding shares of redeemable, convertible preferred stock upon receipt of the consent of a majority of our preferred stockholders. In addition, the numerator in the pro forma diluted net income per share calculation has been adjusted for income resulting from remeasurement of the preferred stock warrant liability as these measurements were no longer required when the preferred stock warrants became warrants to purchase shares of our common stock upon the closing of our initial public offering.
Recently Issued Accounting Standards	'
	(f)	Recently Issued Accounting Standards
	On May 28, 2014, the Financial Accounting Standards Board, or FASB, issued the Accounting Standards Update, or ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606), that will supersede nearly all existing revenue recognition guidance under U.S. GAAP.  This guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The guidance will replace most existing revenue recognition guidance when it becomes effective. The standard will be effective for us for annual and interim periods beginning after December 15, 2016, and early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect that this new guidance will have on our consolidated financial statements and related disclosures. We have not selected a transition method nor have we determined the effect of the standard on our ongoing financial reporting.
Fair Value Measurements	'
	(g)	Fair Value Measurements
	The carrying amounts of financial instruments, including cash and cash equivalents, accrued compensation, accrued clinical holdbacks and accounts payable, approximate fair value due to their short-term maturities. The carrying amount of the convertible note payable approximates its fair value as its terms are comparable to what would be included in similar debt instruments.
	We account for our preferred stock warrants pursuant to ASC Topic 480, Distinguishing Liabilities from Equity, and classify warrants for redeemable preferred stock as liabilities. The warrants are reported as short-term or long-term liabilities, depending on their remaining term, at their estimated fair value at December 31, 2013 and June 30, 2014, and any changes in fair value are reflected in changes in value of warrants.
	The fair value of all the outstanding warrants at December 31, 2013 and June 30, 2014 was $1,564,941 and $7,118,054, respectively.
	In general, asset and liability fair values are determined using the following categories:
	Level 1– inputs utilize quoted prices in active markets for identical assets or liabilities.
	Level 2– inputs include quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
	Level 3– inputs are unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing inputs are unobservable for the terms and are based on our own assumptions about the assumptions that a market participant would use.
	Our financial instruments, including money market investments, warrants, and put options are measured at fair value on a recurring basis. The carrying amount of money market investments as of December 31, 2013 and June 30, 2014 approximates fair value based on quoted prices in active markets, or Level 1 inputs. The carrying amount of outstanding warrants and put options as of December 31, 2013 and June 30, 2014 approximates fair value based on unobservable inputs, or Level 3 inputs, using assumptions made by us, including pricing, volatility, and expected term. There were no transfers between levels for the year ended December 31, 2013 and the three and six months ended June 30, 2014.
	Assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of December 31, 2013 and June 30, 2014:
	Description	December 31,			Quoted			Significant			June 30,			Quoted		Significant
		2013			prices in			unobservable			2014			prices in		unobservable
					active			inputs						active		inputs
					markets for			(Level 3)						markets for		(Level 3)
					identical									identical
					assets									assets
					(Level 1)									(Level 1)
	Assets measured at fair value:
	Money market investments (included in		20,672			20,672			—			20,422			20,422		—
	cash and cash equivalents)
	Liabilities measured at fair value:
	Warrants (included in fair value of		1,564,941			—			1,564,941			7,118,054			—		7,118,054
	warrants)
	Put and call options (included in fair		101,222			—			101,222			3,449,866			—		3,449,866
	value of put and call options and
	other long-term liabilities)
	A reconciliation of the beginning and ending balances of our assets and liabilities measured at fair value using significant unobservable, or Level 3, inputs is as follows:
		Warrants			Put and call options
	Balance of liability at December 31, 2013	$	(1,564,941	)		(101,222	)
	Issuance of warrants in connection with		(5,331,175	)	—
	convertible promissory notes
	Issuance of put and call options in	—				(1,667,136	)
	connection with convertible
	promissory notes
	Income (loss) included in net loss:
	Loss due to change in fair value		(221,938	)		(1,681,508	)
	Balance of liability at June 30, 2014	$	(7,118,054	)		(3,449,866	)
	Gains (losses) included in net income and loss for the six months ended June 30, 2014 are reported in change in value of warrants.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Schedule of Accrued Liabilities	'
	Accrued liabilities consisted of the following as of:
		December 31,			June 30,
		2013			2014
	Accrued compensation	$	278,108			288,672
	Accrued clinical trial holdbacks		126,455			107,196
	Income taxes		115,765		—
	Other		400,634			659,025
	Total Accrued Liabilities	$	920,962			1,054,893
Summary of Basic and Diluted Loss Per Share	'
	Basic net loss per share is computed by dividing net loss applicable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In the periods with net losses, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.
		Three Months Ended June 30,						Six Months Ended June 30,
		2013			2014			2013			2014
	Historical net loss per share:
	Numerator:
	Net loss attributable to GlobeImmune, Inc. common stockholders		(2,140,577	)		(9,151,511	)		(6,913,434	)		(15,033,635	)
	Denominator:
	Weighted-average common shares used in computing		92,430			98,067			92,430			95,622
	net loss per share of common stock - basic and diluted
	Net loss per share of common stock attributable to		(23.16	)		(93.32	)		(74.80	)		(157.22	)
	GlobeImmune, Inc. stockholders - basic and
	diluted
	Pro forma net income per share:
	Numerator:
	Net loss attributable to GlobeImmune, Inc. common stockholders				$	(9,151,511	)				$	(15,033,635	)
	Deduct:  income on change in fair value of warrant					2,150,491						1,903,446
	liability
	Add back:  interest expense on convertible				(*		)				(*		)
	promissory notes
	Add back:  Preferred stock dividends and accretion					3,437,556						6,875,108
	of offering costs to redemption value
	Net income used in computing pro forma net income				$	(3,563,464	)				$	(6,255,081	)
	per share of common stock attributable to
	GlobeImmune, Inc. stockholders - diluted
	Denominator:
	Basic and diluted weighted-average common shares, as					98,067						95,622
	used above
	Add back: pro forma adjustment to reflect weighted-					2,757,825						2,757,825
	average of assumed conversion of convertible
	preferred stock   (1)
	Add back:  pro forma adjustment to reflect weighted-				(*		)				(*		)
	average convertible promissory note on an if-
	converted basis
	Add back:  incremental stock options on a treasury				(*		)				(*		)
	stock method
	Weighted-average shares used in computing pro forma					2,855,892						2,853,447
	diluted net income per common share
	Pro forma net income per share of common stock				$	(1.25	)				$	(2.19	)
	attributable to GlobeImmune, Inc. stockholders -
	diluted
	(*)	Balance and shares were excluded for the three and six months ended June 30, 2014 calculation as they were anti-dilutive.
	-1	The pro forma net income per share reflects the assumed conversion of all outstanding shares of redeemable, convertible preferred stock as of June 30, 2014 into 2,757,825 shares of common stock. This conversion occurred upon the closing of our initial public offering. The numerator in the pro forma diluted net income per share calculation has been adjusted to remove the preferred stock dividends and accretion of offering costs to redemption value as this charge was eliminated upon the conversion of all outstanding shares of redeemable, convertible preferred stock upon receipt of the consent of a majority of our preferred stockholders. In addition, the numerator in the pro forma diluted net income per share calculation has been adjusted for income resulting from remeasurement of the preferred stock warrant liability as these measurements were no longer required when the preferred stock warrants became warrants to purchase shares of our common stock upon the closing of our initial public offering.
Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	Assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of December 31, 2013 and June 30, 2014:
	Description	December 31,			Quoted			Significant			June 30,			Quoted		Significant
		2013			prices in			unobservable			2014			prices in		unobservable
					active			inputs						active		inputs
					markets for			(Level 3)						markets for		(Level 3)
					identical									identical
					assets									assets
					(Level 1)									(Level 1)
	Assets measured at fair value:
	Money market investments (included in		20,672			20,672			—			20,422			20,422		—
	cash and cash equivalents)
	Liabilities measured at fair value:
	Warrants (included in fair value of		1,564,941			—			1,564,941			7,118,054			—		7,118,054
	warrants)
	Put and call options (included in fair		101,222			—			101,222			3,449,866			—		3,449,866
	value of put and call options and
	other long-term liabilities)
Reconciliation of Assets and Liabilities Measured at Fair Value Using Significant Unobservable Level 3 Inputs	'
	A reconciliation of the beginning and ending balances of our assets and liabilities measured at fair value using significant unobservable, or Level 3, inputs is as follows:
		Warrants			Put and call options
	Balance of liability at December 31, 2013	$	(1,564,941	)		(101,222	)
	Issuance of warrants in connection with		(5,331,175	)	—
	convertible promissory notes
	Issuance of put and call options in	—				(1,667,136	)
	connection with convertible
	promissory notes
	Income (loss) included in net loss:
	Loss due to change in fair value		(221,938	)		(1,681,508	)
	Balance of liability at June 30, 2014	$	(7,118,054	)		(3,449,866	)

Deferred_Revenue_Tables

Deferred Revenue (Tables)	6 Months Ended
	Jun. 30, 2014
Components of Deferred Revenue	'
	Deferred revenue consisted of the following as of:
		31-Dec-13			30-Jun-14
	Celgene	$	14,169,164			12,390,655
	Gilead		244,711			35,695
	Total deferred revenue		14,413,875			12,426,350
	Less:  current portion		(3,756,899	)		(3,378,706	)
	Deferred revenue, long-term	$	10,656,976			9,047,644

Liquidity_Risks_Additional_Inf

Liquidity Risks - Additional Information (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]	'	'	'	'	'
Accumulated deficit	$214,303,548	'	$214,303,548	'	$199,321,927
Net income (loss)	-5,713,955	1,080,708	-8,158,527	-470,864	'
Net cash provided by (used in) operating activities	'	'	($5,890,694)	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies [Line Items]	'	'
Reverse Stock Split, description	'On April 25, 2014, we affected a 1-for-4.3 reverse stock split of our common stock after approval by our stockholders.	'
Reverse stock split date	25-Apr-14	'
Accrued clinical trial holdbacks	$107,196	$126,455
Percentage of holdbacks on payments due to entities	5.00%	'
Warrants outstanding, fair value	$7,118,054	$1,564,941

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Schedule of Accrued Liabilities (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Schedule Of Accrued Liabilities [Line Items]	'	'
Accrued compensation	$288,672	$278,108
Accrued clinical trial holdbacks	107,196	126,455
Income taxes	'	115,765
Other	659,025	400,634
Total Accrued Liabilities	$1,054,893	$920,962

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Summary of Basic and Diluted Loss Per Share (Details) (USD $)	3 Months Ended			6 Months Ended
	Jun. 30, 2014		Jun. 30, 2013	Jun. 30, 2014		Jun. 30, 2013
Earnings Per Share Basic [Line Items]	'		'	'		'
Net loss attributable to GlobeImmune, Inc. common stockholders	($9,151,511)		($2,140,577)	($15,033,635)		($6,913,434)
Basic and diluted weighted-average common shares used in computing net loss per share	98,067		92,430	95,622		92,430
Net loss per share of common stock attributable to GlobeImmune, Inc. stockholders - basic and diluted	($93.32)		($23.16)	($157.22)		($74.80)
Noncash expense (income) from change in valuation of warrants and put and call options	2,150,491		-483,393	1,903,446		-969,974
Add back: interest expense on convertible promissory notes	'	[1]	'	'	[1]	'
Add back: Preferred stock dividends and accretion of offering costs to redemption value	3,437,556		'	6,875,108		'
Net income used in computing pro forma net income per share of common stock attributable to GlobeImmune, Inc. stockholders - diluted	($3,563,464)		'	($6,255,081)		'
Add back: pro forma adjustment to reflect weighted- average of assumed conversion of convertible preferred stock	2,757,825	[2]	'	2,757,825	[2]	'
Add back: pro forma adjustment to reflect weighted- average convertible promissory note on an if- converted basis	'	[1]	'	'	[1]	'
Add back: incremental stock options on a treasury stock method	'	[1]	'	'	[1]	'
Weighted-average shares used in computing pro forma diluted net income per common share	2,855,892		'	2,853,447		'
Pro forma net income per share of common stock attributable to GlobeImmune, Inc. stockholders - diluted	($1.25)		'	($2.19)		'
[1]	Balance and shares were excluded for the three and six months ended June 30, 2014 calculation as they were anti-dilutive.
[2]	The pro forma net income per share reflects the assumed conversion of all outstanding shares of redeemable, convertible preferred stock as of June 30, 2014 into 2,757,825B shares of common stock. This conversion occurred upon the closing of our initial public offering. The numerator in the pro forma diluted net income per share calculation has been adjusted to remove the preferred stock dividends and accretion of offering costs to redemption value as this charge was eliminated upon the conversion of all outstanding shares of redeemable, convertible preferred stock upon receipt of the consent of a majority of our preferred stockholders. In addition, the numerator in the pro forma diluted net income per share calculation has been adjusted for income resulting from remeasurement of the preferred stock warrant liability as these measurements were no longer required when the preferred stock warrants became warrants to purchase shares of our common stock upon the closing of our initial public offering.

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Summary of Basic and Diluted Loss Per Share (Parenthetical) (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2014		Jun. 30, 2014
Earnings Per Share Basic [Line Items]	'		'
Conversion of outstanding shares of redeemable, convertible preferred stock into common stock	2,757,825	[1]	2,757,825	[1]
[1]	The pro forma net income per share reflects the assumed conversion of all outstanding shares of redeemable, convertible preferred stock as of June 30, 2014 into 2,757,825B shares of common stock. This conversion occurred upon the closing of our initial public offering. The numerator in the pro forma diluted net income per share calculation has been adjusted to remove the preferred stock dividends and accretion of offering costs to redemption value as this charge was eliminated upon the conversion of all outstanding shares of redeemable, convertible preferred stock upon receipt of the consent of a majority of our preferred stockholders. In addition, the numerator in the pro forma diluted net income per share calculation has been adjusted for income resulting from remeasurement of the preferred stock warrant liability as these measurements were no longer required when the preferred stock warrants became warrants to purchase shares of our common stock upon the closing of our initial public offering.

Summary_of_Significant_Account7

Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) (Fair Value, Measurements, Recurring, USD $)	Jun. 30, 2014	Dec. 31, 2013
Assets measured at fair value:	'	'
Money market investments (included in cash and cash equivalents)	$20,422	$20,672
Liabilities measured at fair value:	'	'
Warrants (included in fair value of warrants)	7,118,054	1,564,941
Put and call options (included in fair value of put and call options and other long-term liabilities)	3,449,866	101,222
Quoted prices in active markets for identical assets (Level 1)	'	'
Assets measured at fair value:	'	'
Money market investments (included in cash and cash equivalents)	20,422	20,672
Significant unobservable inputs (Level 3)	'	'
Liabilities measured at fair value:	'	'
Warrants (included in fair value of warrants)	7,118,054	1,564,941
Put and call options (included in fair value of put and call options and other long-term liabilities)	$3,449,866	$101,222

Summary_of_Significant_Account8

Summary of Significant Accounting Policies - Reconciliation of Assets and Liabilities Measured at Fair Value Using Significant Unobservable Level 3 Inputs (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Put Options	'
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]	'
Balance of liability, beginning balance	($101,222)
Issuance of put and call options in connection with convertible promissory notes	-1,667,136
Income (loss) included in net loss:	'
Loss due to change in fair value	-1,681,508
Balance of liability, ending balance	-3,449,866
Warrant	'
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]	'
Balance of liability, beginning balance	-1,564,941
Issuance of warrants in connection with convertible promissory notes	-5,331,175
Income (loss) included in net loss:	'
Loss due to change in fair value	-221,938
Balance of liability, ending balance	($7,118,054)

Convertible_Notes_Additional_I

Convertible Notes - Additional Information (Details) (USD $)

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

1 Months Ended

2 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

2 Months Ended

6 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Nov. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Nov. 30, 2013

Feb. 28, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Feb. 28, 2014

Feb. 28, 2014

Jun. 30, 2014

Jun. 30, 2014

2013 Notes

2013 Notes

2013 Notes

2013 Notes

2013 Notes

2014 Convertible Notes

2014 Convertible Notes

2014 Convertible Notes

2014 Convertible Notes

2014 Convertible Notes

2014 Convertible Notes

2014 Convertible Notes

2014 Convertible Notes

2014 Convertible Notes

IPO

Debt

Debt

Call And Put option

Warrant

Warrant

IPO

Warrant

Call And Put option

Equity

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible promissory note

$247,948

$197,955

$391,730

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible promissory note , interest rate

'

'

8.00%

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

Debt instrument, expiry period

'

'

'3 years

'

'

'

'10 years

'

'

'

'

'

'

'

'5 years

'

Discount from IPO price

'

'

80.00%

'

'

'

'

'

'

'

'

'

'

'

'

70.00%

Warrant coverage percentage of notes

'

'

30.00%

'

'

'

'

'

'

100.00%

'

'

'

'

'

'

Fair value of warrants upon issuance

'

'

'

'

106,087

'

'

4,454,397

'

'

'

'

'

'

'

'

Fair Value upon issuance of option

'

'

'

101,222

101,222

'

'

'

'

'

'

'

1,667,136

'

'

'

Total Debt Discount

3,388,319

'

207,309

'

'

'

'

'

'

'

'

'

'

6,121,533

'

'

Amortization of debt discount

'

'

'

17,213

34,236

'

'

'

1,530,383

2,559,639

'

'

'

'

'

'

Unamortized balance of the debt instrument

'

'

'

163,804

163,804

198,041

'

'

3,570,894

3,570,894

'

'

'

'

'

'

Accrued interest

'

'

'

'

20,022

4,266

'

'

'

297,543

'

'

'

'

'

'

Convertible notes payable

'

'

'

'

'

'

'

7,500,000

'

'

'

'

'

'

'

'

Debt instrument, maturity date

'

'

'

'

'

'

'

31-Jan-15

'

'

'

'

'

'

'

'

Debt issuance costs

'

'

'

'

'

'

'

1,928,265

'

'

'

'

'

'

'

'

Fair value of warrants issued with 2014 convertible notes

876,778

'

'

'

'

'

'

876,778

'

'

'

'

'

'

'

'

Amortization of debt issuance costs

'

'

'

'

'

'

'

'

'

'

482,066

803,444

'

'

'

'

Unamortized balance of the debt instrument issuance cost

'

'

'

'

'

'

'

'

'

'

$1,124,821

$1,124,821

'

'

'

'

Deferred_Revenue_Components_of

Deferred Revenue - Components of Deferred Revenue (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Deferred Revenue Arrangement [Line Items]	'	'
Total deferred revenue	$12,426,350	$14,413,875
Less: current portion	-3,378,706	-3,756,899
Deferred revenue	9,047,644	10,656,976
Celgene	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Total deferred revenue	12,390,655	14,169,164
Gilead	'	'
Deferred Revenue Arrangement [Line Items]	'	'
Total deferred revenue	$35,695	$244,711

Deferred_Revenue_Additional_In

Deferred Revenue - Additional Information (Details) (USD $)

3 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

1 Months Ended

36 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jul. 31, 2013

Apr. 30, 2012

Oct. 31, 2011

31-May-09

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Jul. 31, 2013

Apr. 30, 2012

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Nov. 30, 2011

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Jun. 30, 2014

Celgene

Celgene

Celgene

Celgene

Celgene

Celgene

Celgene

Celgene

Celgene

Celgene

Celgene

Celgene

Celgene

Celgene

Celgene

Celgene

Celgene

Gilead

Gilead

Gilead

Gilead

Gilead

Gilead

Gilead

Gilead

Gilead

Products

License

Undelivered Items

May 2009 to April 2012

Maximum

Development And Regulatory Milestones

GI-6200

GI-6200

GI-6301

GI-6301

Development And Regulatory Milestones

Sales Milestone

Maximum

Maximum

Development And Regulatory Milestones

Maximum

Development And Regulatory Milestones

Maximum

Maximum

Deferred Revenue Arrangement [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collaboration and Option agreement date

'

'

'

'

'

'

'

'

'

'

31-May-09

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of oncology products

'

'

'

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Upfront payment received

'

'

'

'

$9,000,000

'

'

'

'

'

'

'

'

'

$31,300,000

'

'

'

'

'

'

$10,000,000

'

'

'

'

'

'

'

'

Initial nonrefundable payment received

'

'

'

'

'

300,000

1,000,000

30,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net sales milestones amount to be recognized

'

'

'

'

'

'

'

'

'

'

'

'

'

233,119

'

60,000,000

101,000,000

60,000,000

85,000,000

60,000,000

85,000,000

'

'

'

'

'

'

'

130,000,000

40,000,000

Collaboration license and services

1,153,018

2,573,497

2,436,539

3,765,764

'

'

'

'

'

'

'

'

8,766,881

'

'

'

'

'

'

'

'

'

1,373

1,741,829

218,646

2,086,061

'

'

'

'

Research and development services revenue recognized

'

'

'

'

'

'

'

'

819,767

819,767

1,778,510

1,667,803

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Costs of collaboration license and services

925,141

536,276

1,757,995

2,649,192

'

'

'

'

742,902

390,202

1,356,857

1,496,486

'

'

'

'

'

'

'

'

'

'

182,239

146,074

401,138

1,179,706

'

'

'

'

Milestones

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

2,000,000

'

'

Manufacturing services

578,000

1,648,700

712,825

2,588,700

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

578,000

1,648,700

712,825

2,588,700

'

'

'

'

Costs of manufacturing services

$578,000

$1,648,700

$712,825

$2,588,700

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$578,000

$1,648,700

$712,825

$2,588,700

'

'

'

'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Details)	6 Months Ended
	Jun. 30, 2014
Income Taxes [Line Items]	'
Deferred tax assets valuation allowance percent	100.00%

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Details) (USD $)	6 Months Ended					0 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Jul. 08, 2014	Jul. 08, 2014	Jul. 08, 2014	Jul. 08, 2014
			Subsequent Event	Subsequent Event	2014 Convertible Notes	IPO
				2013 Notes	Subsequent Event	Subsequent Event
Subsequent Event [Line Items]	'	'	'	'	'	'
Sale of common stock	98,226	92,812	'	'	'	1,725,000
Sale of stock, price per share	'	'	'	'	'	$10
Proceeds from sale of common stock	$25,513	'	'	'	'	$17,250,000
Conversion of preferred stock into common stock	'	'	2,757,825	'	'	'
Conversion of preferred stock warrants into common stock	'	'	'	51,556	1,116,372	'
Conversion of preferred stock warrants into common stock warrant	'	'	'	12,373	750,000	'